Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authoritiesBusiness Overview: SPL is global research driven pharmaceutical company which develops and manufactures pharmaceutical products for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with...
Senores Pharma's board approved an ESOS 2026 of 0.0472 Cr options for employees (subject to shareholder approval). The company also decided to incorporate wholly-owned subsidiaries in Mexico and Canada to expand its international market presence.
Senores Pharma's Registrar & Share Transfer Agent, MUFG Intime, has updated its investor communication email and introduced a dedicated website for shareholder service requests. Investors should note the new contact points.
Senores Pharmaceuticals' key subsidiary, Havix, has successfully completed its USFDA inspection at its manufacturing facility in Georgia, USA. The inspection concluded with 3 procedural and minor 483 observations. Havix is committed to swiftly responding to these observations within 15 days. This outcome is positive for Senores, as it indicates a...
Senores Pharmaceuticals has announced a board meeting to consider the financial results for the quarter and half-year. The company has increased its stake in its US-based subsidiary, Havix Group Inc. (Aavis Pharmaceuticals), by acquiring 2.97% additional shares for USD 181 per share, raising its total holding to 73.04%. Havix’s turnover...
Senores Pharmaceuticals has announced a board meeting to consider the financial results for the quarter and half-year. The company has acquired 7,914 equity shares of Havix Group Inc. (Aavis Pharmaceuticals) and is awaiting RBI approval to complete the acquisition of the remaining 540 shares, with the approval timeline extended by...
